This page summarises findings from published academic literature. It does not describe or endorse use in humans or animals.
KLOW is a multi-peptide research reference material combining four compounds in a single vial: BPC-157, TB-500, GHK-Cu and KPV. Each has its own established research literature. What makes the combination interesting as a research subject is not that the four do the same thing, but that they are studied at four different points in overlapping biological processes.
KLOW is not a compound in its own right. It is a blend, and the research literature that applies to it is the literature on its four constituents.
BPC-157 is a synthetic pentadecapeptide derived from a sequence found in body protection compound, a protein isolated from gastric juice. Published research examines it in angiogenic signalling and growth factor pathways.
TB-500 is a synthetic fragment related to thymosin beta-4, a naturally occurring protein. The published literature centres on actin sequestration and cytoskeletal dynamics.
GHK-Cu is a copper-binding tripeptide, glycyl-L-histidyl-L-lysine complexed with copper. Research examines its role in extracellular matrix signalling and fibroblast gene expression.
KPV is the C-terminal tripeptide of alpha-melanocyte stimulating hormone, retaining the anti-inflammatory signalling properties of the parent molecule in a much smaller and more stable form.
The four constituents are studied across four distinct but adjacent fields.
Regenerative and tissue repair research accounts for most of the BPC-157 and TB-500 literature, largely in animal and cell models examining angiogenesis and cytoskeletal reorganisation.
Extracellular matrix research is where GHK-Cu sits, with a substantial body of work on fibroblast behaviour and matrix protein expression in dermal cell models.
Inflammatory pathway research covers KPV, which has been examined in epithelial and gut biology models for its relationship to alpha-MSH signalling.
Longevity-associated pathway research draws on all four to varying degrees, generally as one input among many rather than as a primary subject.
The scientific interest in multi-peptide preparations is a question about levels of action, not about additive effects.
Each of the four operates at a different level. BPC-157 is examined largely at the level of vascular signalling. TB-500 at the level of the cytoskeleton. GHK-Cu at the level of the extracellular matrix. KPV at the level of inflammatory mediators.
That spread is the point. A researcher examining a process that involves several of those levels at once has, in principle, a reason to look at them together rather than separately. Whether combined preparations behave as the sum of their constituents is itself an open question in the literature, and one that in vitro work is well suited to examining.
Note also the practical variable: four peptides in one vial is a different preparation to four vials, and the stability and interaction characteristics of a blend are a legitimate research subject in their own right.
| Constituent | Structural class | Primary published research area |
|---|---|---|
| BPC-157 | Synthetic pentadecapeptide | Angiogenic and growth factor signalling |
| TB-500 | Synthetic fragment related to thymosin beta-4 | Actin sequestration and cytoskeletal dynamics |
| GHK-Cu | Copper-binding tripeptide | Extracellular matrix and fibroblast gene expression |
| KPV | Alpha-MSH C-terminal tripeptide | Inflammatory pathway signalling in epithelial models |
No. KLOW is a blend of four separate peptides supplied in one vial. Each constituent has its own distinct structure and its own body of published research. It should be understood as four research subjects presented together, not as one.
Because they are examined at different levels of the same broad processes. BPC-157 in vascular signalling, TB-500 in cytoskeletal dynamics, GHK-Cu in the extracellular matrix, and KPV in inflammatory mediators. Whether a combined preparation behaves as the sum of its constituents is an open research question.
No. KLOW is not a licensed medicine in the United Kingdom, and neither are any of its four constituents. PerformanceLabsUK is not a pharmacy, a pharmaceutical company or a medical provider.
No. All compounds discussed on this site are supplied strictly for in vitro laboratory research use only, and are not intended for human or animal administration.
No. This page is provided for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional for any medical concern.
Compounds studied in this area are listed under Tissue Remodelling Research Peptides and Copper and Dermal Research Peptides.
PerformanceLabsUK Ltd supplies independently tested research reference materials for in vitro laboratory investigation. We are not a pharmacy, pharmaceutical company, or medical provider. All products are supplied for research use only.
You must be of legal age to enter this site.
WARNING: This website contains age-restricted content.
Join the list for new compound drops, batch COAs, and plain English research notes. Your code arrives straight away.
All products are supplied strictly for in vitro laboratory research use. Not for human or veterinary consumption.